Human platelet lysate: better than FCS for osteogenesis
2020
Heidelberg University Hospital, Heidelberg, Germany(1)
Orthopaedic University Hospital Heidelberg, Heidelberg, Germany(2)
Orthopaedic University Hospital Heidelberg, Heidelberg, Germany(2)
Fetal calf serum (FCS / FBS) is frequently used as a growth factor and protein source in bone-marrow-derived mesenchymal stromal cell (BMSC) culture media, although it is a xenogenic product presenting multiple disadvantages. A promising alternative for FCS is human platelet lysate (hPL), which is produced out of human platelet concentrates and happens to be a stable and reliable protein source. In this study, the authors investigated the influence of hPL on the proliferation and osteogenic differentiation capacity of human BMSC. Both the proliferation rate and the differentiation of BMSC cultured in medium supplemented with hPL exceeded those in the presence of FCS. These results show that hPL can replace FCS as a protein supplier in cell culture media and does not negatively affect the osteogenic differentiation capacity of BMSC.
Human platelet lysate can replace fetal calf serum as a protein source to promote expansion and osteogenic differentiation of human bone-marrow-derived mesenchymal stromal cells
Raban Heller(1), Fabian Westhauser(1), Joerg Fellenberg(2)
Added on: 01-29-2021
[1] https://www.mdpi.com/2073-4409/9/4/918/htm